抄録
Regulatory T cells (Tregs) are CD4+ T cells that inhibit autoreactive effector T cells to suppress antitumor immunity. Many anticancer therapeutics have limited efficacy, and it is thought that Tregs may, in part, be one of the reasons. From this viewpoint, Tregs may be a therapeutic target for cancer immunotherapy. Tregs also play a pivotal role in the induction of self-tolerance, and their dysfunction may lead to autoimmune disease. Promising results have recently been reported on the molecular targeting of drugs to Tregs. In the near future, the regulation of Tregs may be a central point for cancer immunotherapy. In this chapter, we focus on the immune-suppressing mechanism of Tregs and the development of strategies to modulate Tregs.
本文言語 | 英語 |
---|---|
ホスト出版物のタイトル | Immunotherapy of Cancer |
ホスト出版物のサブタイトル | An Innovative Treatment Comes of Age |
出版社 | Springer Japan |
ページ | 309-322 |
ページ数 | 14 |
ISBN(電子版) | 9784431550310 |
ISBN(印刷版) | 9784431550303 |
DOI | |
出版ステータス | 出版済み - 2月 22 2016 |
!!!All Science Journal Classification (ASJC) codes
- 医学一般